Literature DB >> 28765406

A contemporary review of peripartum cardiomyopathy.

Peysh A Patel1,2, Ashwin Roy3,2, Rabeia Javid4,2, John Aw Dalton5.   

Abstract

Peripartum cardiomyopathy reflects the presence of cardiac failure in the absence of determinable heart disease and occurs in late third trimester of pregnancy or up to 6 months postpartum. A full understanding of pathophysiological mechanisms is lacking, but excess prolactin levels, haemodynamic alterations, inflammation and nutritional deficiencies have all been implicated. Its clinical presentation has distinct overlap with physiological alterations in healthy pregnancy and this presents a diagnostic challenge. However, echocardiography can provide significant benefit in accurate assessment and narrowing of differentials. Pharmacotherapy is broadly aligned with established guidelines for cardiac failure, but specific therapies are indicated for treatment of clinical sequelae. Moreover, an individualistic approach is required based on clinical context to manage delivery. Further research appears imperative to optimise management strategies and reduce disease burden. © Royal College of Physicians 2017. All rights reserved.

Entities:  

Keywords:  Cardiac failure; cardiomyopathy; peripartum; pregnancy; ventricular dysfunction

Mesh:

Year:  2017        PMID: 28765406      PMCID: PMC6297639          DOI: 10.7861/clinmedicine.17-4-316

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  37 in total

1.  Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy.

Authors:  U Elkayam; P P Tummala; K Rao; M W Akhter; I S Karaalp; O R Wani; A Hameed; I Gviazda; A Shotan
Journal:  N Engl J Med       Date:  2001-05-24       Impact factor: 91.245

2.  Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review.

Authors:  G D Pearson; J C Veille; S Rahimtoola; J Hsia; C M Oakley; J D Hosenpud; A Ansari; K L Baughman
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

3.  Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy.

Authors:  Olaf Forster; Denise Hilfiker-Kleiner; Aftab A Ansari; J Bruce Sundstrom; Elena Libhaber; Winnie Tshani; Anthony Becker; Anthony Yip; Gunnar Klein; Karen Sliwa
Journal:  Eur J Heart Fail       Date:  2008-09-02       Impact factor: 15.534

Review 4.  Autoimmune mechanisms as the basis for human peripartum cardiomyopathy.

Authors:  Aftab A Ansari; James D Fett; Robert E Carraway; Ann E Mayne; Nattawat Onlamoon; J Bruce Sundstrom
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

Review 5.  Glucocorticoids and lung development in the fetus and preterm infant.

Authors:  R J Bolt; M M van Weissenbruch; H N Lafeber; H A Delemarre-van de Waal
Journal:  Pediatr Pulmonol       Date:  2001-07

6.  Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy.

Authors:  C L Hu; Y B Li; Y G Zou; J M Zhang; J B Chen; J Liu; Y H Tang; Q Z Tang; C X Huang
Journal:  Heart       Date:  2006-10-25       Impact factor: 5.994

7.  The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy.

Authors:  Karen Sliwa; Daniel Skudicky; Geoffrey Candy; Anette Bergemann; Mark Hopley; Pinhas Sareli
Journal:  Eur J Heart Fail       Date:  2002-06       Impact factor: 15.534

8.  High prevalence of viral genomes and inflammation in peripartum cardiomyopathy.

Authors:  Burkhard D Bültmann; Karin Klingel; Michael Näbauer; Diethelm Wallwiener; Reinhard Kandolf
Journal:  Am J Obstet Gynecol       Date:  2005-08       Impact factor: 8.661

9.  Myocarditis and long-term survival in peripartum cardiomyopathy.

Authors:  G M Felker; C J Jaeger; E Klodas; D R Thiemann; J M Hare; R H Hruban; E K Kasper; K L Baughman
Journal:  Am Heart J       Date:  2000-11       Impact factor: 4.749

10.  A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy.

Authors:  Denise Hilfiker-Kleiner; Karol Kaminski; Edith Podewski; Tomasz Bonda; Arnd Schaefer; Karen Sliwa; Olaf Forster; Anja Quint; Ulf Landmesser; Carola Doerries; Maren Luchtefeld; Valeria Poli; Michael D Schneider; Jean-Luc Balligand; Fanny Desjardins; Aftab Ansari; Ingrid Struman; Ngoc Q N Nguyen; Nils H Zschemisch; Gunnar Klein; Gerd Heusch; Rainer Schulz; Andres Hilfiker; Helmut Drexler
Journal:  Cell       Date:  2007-02-09       Impact factor: 41.582

View more
  3 in total

Review 1.  Peripartum cardiomyopathy: disease or syndrome?

Authors:  Lucia Baris; Jérôme Cornette; Mark R Johnson; Karen Sliwa; Jolien W Roos-Hesselink
Journal:  Heart       Date:  2019-02-12       Impact factor: 5.994

2.  ZFP36L2 suppresses mTORc1 through a P53-dependent pathway to prevent peripartum cardiomyopathy in mice.

Authors:  Hidemichi Kouzu; Yuki Tatekoshi; Hsiang-Chun Chang; Jason S Shapiro; Warren A McGee; Adam De Jesus; Issam Ben-Sahra; Zoltan Arany; Jonathan Leor; Chunlei Chen; Perry J Blackshear; Hossein Ardehali
Journal:  J Clin Invest       Date:  2022-05-16       Impact factor: 19.456

Review 3.  Peripartum cardiomyopathy: a review.

Authors:  Corina Iorgoveanu; Ahmed Zaghloul; Mahi Ashwath
Journal:  Heart Fail Rev       Date:  2021-06-17       Impact factor: 4.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.